RBC Capital analyst Kennen MacKay weighed in on news that Ra Pharmaceuticals (NASDAQ: RARX) agreed to be ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE